Steven Cohen Praxis Precision Medicines, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.71 $144,611 - $284,236	-166,220 Reduced 1.58%	10,383,780 $17.8 Million
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $8.72 Million - $12.4 Million	10,500,000 Added 21000.0%	10,550,000 $12.1 Million
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $40,000 - $249,000	-50,000 Reduced 50.0%	50,000 $40,000
Q2 2022 Aug 15, 2022	SELL	$1.75 - $11.34 $2.15 Million - $13.9 Million	-1,228,943 Reduced 92.48%	100,000 $245,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $1.2 Million - $2.38 Million	-117,450 Reduced 8.12%	1,328,943 $13.6 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $5.19 Million - $7.11 Million	309,398 Added 27.21%	1,446,393 $28.5 Million
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $4.6 Million - $7.9 Million	350,000 Added 44.47%	1,136,995 $21 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $11.9 Million - $21.5 Million	650,000 Added 474.47%	786,995 $14.4 Million
Q1 2021 May 17, 2021	SELL	$29.34 - $60.2 $3.32 Million - $6.8 Million	-113,005 Reduced 45.2%	136,995 $4.49 Million
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $6.81 Million - $14 Million	250,000 New	250,000 $13.8 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.